Prospective study in critically ill non-neutropenic patients: Diagnostic potential of (1,3)-β-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 5, 2012, Pages 721-731

  Acosta, J ^a   Catalan, M ^a   Del Palacio Perez Medel A ^a   Montejo, J C ^a   De La Cruz Bertolo J ^a   Moragues, M D ^b   Ponton J ^b   Finkelman, M A ^c   Del Palacio, A ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c Associates of Cape Cod Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; BETA 1,3 GLUCAN; CASPOFUNGIN; GALACTOMANNAN; PIPERACILLIN PLUS TAZOBACTAM; VORICONAZOLE;

ABDOMINAL ABSCESS; ADULT; AGED; ARTICLE; ASPERGILLUS; AUTOPSY; BIOPSY; BLOOD CULTURE; CANDIDA; CARBOHYDRATE ANALYSIS; CASE CONTROL STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HIGH RISK PATIENT; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; MOULD; MYCELIUM; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMIC MYCOSIS; ZYGOMYCOSIS;

ADULT; AGED; AGED, 80 AND OVER; BETA-GLUCANS; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MANNANS; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES; ROC CURVE; SEPSIS;

EID: 84862878334     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1365-0     Document Type: Article

References (50)

1. Roosen J, Frans E, Wilmer A, Knockaert D, Bobbaers H (2000) Comparison of premortem clinical diagnoses in critically ill patients and subsequent autopsy findings. Mayo Clin Proc 75:562-567
2. Blot S,Vandewoude K (2004)Management of invasive candidiasis in critically ill patients. Drugs 64:2159-2175
3. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E (2007) Invasive aspergillosis in the intensive care unit. Clin Infect Dis 45:205-216
4. Hope WW, Walsh TJ, Denning DW (2005) Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 5:609-622
5. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Disease Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-1821
6. Maertens J, Meersseman W, Bleyenbergh PV (2009) New therapies for fungal pneumonia. Curr Opin Infect Dis 22:183-190
7. Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D (2003) Serum glucan levels are not specific for presence of fungal infections in Intensive Care Unit patients. Clin Diagn Lab Immunol 10:882-885
8. Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, Spriet I, Verbeken E, VanWijngaerden E (2008) Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 177:27-34
9. Ostrosky-Zeichner L, Alexander B, Kett D, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, Finkelman MA, Rex JH (2005) Multicenter clinical evaluation of the (1→ 3)- β-D-glucan assay as an aid to diagnosis of fungal Infections in humans. Clin Infect Dis 41:654-659
10. León C, Ruiz-Santana S, Saavedra P, Galván B, Blanco A, Castro C, Balasini C, Utande-Vázquez A, Gonzalez de Molina FJ, Blasco-Navalproto MA, López MJ, Charles PE, Martin E, Hernández-Viera MA (2009) Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 37:1624-1633
11. Tissot E et al (2010) 50th Interscience Conference Antimicrobial Agents Chemotherapy; -1071
12. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH (2007) Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 26:271-276
13. Cornillet A, Camus C, Imubona S, Gandemer V, Tattevin P, Belleguic C, Chevrier S, Meunier C, Lebert C, Aupée M, Caulet- Maugendre S, Faucheux M, Lelong B, Leray E, Guigen C, Gangneux JP (2006) Comparison of epidemiological, clinical and biological features of invasive aspergillosis in neutropenic and non-neutropenic patients: a 6-year survey. Clin Infect Dis 43:577-584
14. Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, Wingard JR, Herbrecht R, Ribaud P, Patterson TF, Troke PF, Denning DW, Bennett JE, De Pauw BE, Rubin RH (2007) Imaging findings in acute invasive aspergillosis: clinical significance of the halo sign. Clin Infect Dis 44:373-379
15. McMullan R, Metwally L, Coyle PV, Hedderwick S, McCloskey B, O'Neill HJ (2008) A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of Candidemia in nonneutropenic, critically ill patients. Clin Infect Dis 46:890-896
16. De Hoog GS, Guarro J, Gené J, Figueras MJ (2000) Atlas of clinical fungi, 2nd edn. Centraalbureau voor Schimmelcultures, Utrecht
17. Pazos C, Pontón J, del Palacio A (2005) Contribution of (1-3)- β-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 43:299-305
18. Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristics (ROC) curve. Radiology 143:29-36
19. Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A (2008) Contribution of the (1?3)-{beta}-D-glucan assay for the diagnosis of invasive fungal infections. J Clin Microbiol 46:1009-1013
20. Obayashi T, Neigishi K, Susuki T, Funata N (2008) Reappraisal of the serum (1→3)-β-D-glucan assay for the diagnosis of invasive fungal infections-a study based on autopsy cases from 6 years. Clin Infect Dis 46:1864-1870
21. Koo S, Bryar JM, Page JH, Baden LR, Marty FM (2009) Diagnostic performance of the (1-3)-β-D-glucan assay for invasive fungal disease. Clin Infect Dis 49:1650-1659
22. Eggimann P, Ostrosky-Zeichner L (2010) Early antifungal intervention strategies in ICU patients. Curr Opin Crit Care 16:465-469
23. Maertens J, Verhaegen J, Demuynck H, Brock P, Verhoef G, Vandenberghe P, Van Eldere J, Verbist L, Boogaerts M (1999) Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol 37:3223-3228
24. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97:1604-1610
25. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over 15 year period (1989- 2003). Haematologica 91:986-989
26. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41:1242-1250
27. Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, Van Wijngaerden E (2009) Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 35:1526-1531
28. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1988) Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 148:2642-2645
29. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller MA, Diekema D (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37:1172-1177
30. Balloy V, Huerre M, Latgé JP, Chignard M (2005) Differences in patterns of infection and inflammation for corticosteroids treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 73:494-503
31. Mennink-Kersten MA, Donnelly JP, Verweij PE (2004) Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 4:349-357
32. Marr KA, Laverdiere M, Gugel A, Leisenring W (2005) Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 40:1762-1769
33. Von Eiff M, Roos N, Schulten R, Heese M, Zuhlsdorf M, van de Loo J (1995) Pulmonary aspergillosis: early diagnosis improves survival. Respiration 62:341-347
34. Pazos C, Moragues MD, Quindós G, Pontón J, del Palacio A (2006) Diagnostic potential of (1,3)-beta-D-glucan and anti- Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive Candidiasis in neutropenic adult patients. Rev Iberoam Micol 23:209-215
35. Marty FM, Koo S, Bryar J, Baden LR (2007) (1→3) beta- D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 147:70-72
36. Cuetara MS, Alhambra A, Chaves F, Moragues MD, Ponton J, del Palacio A (2008) Use of a serum (1-3)-β-D-glucan assay for diagnosis and follow-up of Pneumocystis jiroveci pneumonia. Clin Infect Dis 47:1364-1366
37. Mennink-Kersten MA, Verweij PE (2006) Non-culture based diagnostics for opportunistic fungi. Infect Dis Clin North Am 20:711-727
38. Mennink-KerstenMA,Warris A, Verweij PE (2006) 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 354:2834-2835
39. Mennink-Kersten MA, Ruegebrink D, Verweij PE (2008) Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis 46:1930-1931
40. Del Palacio A, Alhambra A, Cuetara MS, Ponton J (2007) Estado actual del diagnóstico precoz de las infecciones invasoras causadas por Aspergillus y otros hongos filamentosos emergentes. Rev Iberoam Micol 24:187-197
41. Maertens J, Theunissen K, Lagrou K (2010) Reply to Rijnders and Slobbe and to Donelly and Leeflang. Clin Infect Dis 50:1071-1073
42. Mohr J et al (2005) 45th Interscience Conference on Antimicrobial Agents and Chemotherapy-168
43. Mohr J, Sims C, Paetznick V, Rodriguez J, Finkelman M, Rex JH, Ostrosky-Zeichner L (2011) Prospective survey of (1→3)- β-D-glucan and its relationship to invasive candidiasis in the surgical ICU setting. J Clin Microbiol 49:58-61
44. Samonis G, Kofteridis DP, Maraki S, Alegakis D, Mantadakis E, Papadakis JA, Gikas AH, Falagas ME (2005) Levofloxacin and moxifloxacin increase human gut colonization by Candida species. Antimicrob Agents Chemother 49:5189
45. Desmet S, Van Wijngaerden E, Maertens J, Verhaegen J, Verbeken E, De Munter P, Meersseman W, Van Meensel B, Van Eldere J, Lagrou K (2009) Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 47:3871-3874
46. Kanamori H, Kanemitsu K, Miyasaka T, Ameku K, Endo S, Aoyagi T, Inden K, Hatta M, Yamamoto N, Kunishima H, Yano H, Kaku K, Hirakata Y, Kaku M (2009) Measurement of (1-3)- beta-D-glucan derived from different gauze types. Tohoku J Exp Med 217:117-121
47. Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640-3645
48. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43:25-31
49. Kawazu M, Kanda Y, Nannya Y, Aoki K, Kurokawa M, Chiba S, Motokura T, Hirai H, Ogawa S (2004) Prospective comparison of the diagnosis potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1→3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 42:2733-2741
50. Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, Matsuura S, Duvoisin B, Bille J, Calandra T, Marchetti O (2008) 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 46:878-885